GlobeImmune, Inc. closed a $41.2MM Series C financing. The round was led by Wexford Capital, other participants include Celgene (NASDAQ: CELG), Mellon Family Investment Company, Richard King Mellon Foundation, Eminent Venture Capital Corp., Boston Life Science Venture, and WRF Capital. Previous investors who participated in the round include HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica Venture Partners, Adams Street Partners, Biogen Idec (NASDAQ: BIIB), Pac-Link Bioventures, China Investment and Development, Yasuda Enterprise Development, Partners Healthcare, and GC&H Investments.
This financing should carry GlobeImmune through to primary endpoints of their Phase II trials of GI-5005 for chronic hepatitis C and GI-4000 for resectable pancreatic cancer. In addition, it may launch pre-clinical Tarmogen™ candidates into the clinic. The company has raised approximately $88MM to date and has attracted local, costal and international dollars from venture, corporate and foundation sources. Truly an incredible close and needless to say how excited we are to observe GI-4000 and 5005 move through the clinic.